Kymab Racing for a U.S. IPO Listing in 3rd Quarter of 2020.
- Monday, April 6, 2020, 7:20
- Uncategorized
- Add a comment
Based in Cambridgeshire, Kymab is discovering and developing human monoclonal antibody therapeutics with an initial focus on malaria and HIV.
About the Author
admin123 has written 23402 stories on this site.
